Sign in

GBG

@gbg.de
106 followers 155 following 120 posts

Healing through innovation, competence and partnership. #BreastCancer #CancerResearch #ClinicalTrials www.gbg.de

PostsRepliesMedia
GBG @gbg.de · 16h
⛔ Need professional support with your clinical trial ❓ ➡️ From study design and planning to implementation and data management ⬅️ If you are planning a clinical trial or looking for an experienced partner to help bring your research project forward, get in touch with us.
010
GBG @gbg.de · 02/10/2026
What if a clinical trial does not show the result we hoped for? That is not a failure. It is an important scientific finding. The international phase III NSABP-B-59/GBG-96-GeparDouze trial has now been published in Nature Medicine. Read more here: www.nature.com/articles/s41...
000
GBG @gbg.de · 02/10/2026
October is Breast Cancer Awareness Month. At the @GBG, we develop and conduct clinical trials with high quality to answer these questions – together with patients, physicians, study centres and research partners. #BreastCancerAwarenessMonth #BreastCancer #GBG #ClinicalTrials #CancerResearch
000
GBG @gbg.de · 03/09/2026
#GAIN-2 #GBG68: More intensive #chemotherapy, better response does not necessarily mean better #survival. Read the publication: www.nature.com/articles/s41... #ClinicalTrials #Neoadjuvant #adjuvant #GBG
000
GBG @gbg.de · 02/09/2026
New publication in Nature Medicine: The phase 3 NSABP B-59/GeparDouze trial, jointly conducted by the #NSABP Foundation and #GBG. An important step toward more precise, biomarker-driven treatment in TNBC: the right immunotherapy for the right patient. Nature Medicine: www.nature.com/articles/s41...
021
GBG @gbg.de · 17/08/2026
📢 Small residual disease, big impact: lymph node #micrometastases after neoadjuvant therapy were linked to >2.5x higher recurrence risk and >3x higher mortality risk in a new #GBG/AGO-B analysis. #BreastCancer #AxillarySurgery #CancerResearch www.thebreastonline.com/article/S096... #BreastCancer
000
GBG @gbg.de · 12/05/2026
#ESMOBC: new analyses from the Phase III #INAVO120 trial evaluating inavolisib in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive/HER2-negative endocrine-resistant advanced breast cancer. Visit our website: www.gbg.de/en/news/deta...
000
GBG @gbg.de · 08/05/2026
New data from #ESMOBC The #GeparPiPPa study showed a manageable safety profile for chemotherapy-free treatment with #inavolisib, endocrine therapy, and dual #HER2 blockade in HR+/HER2+/PIK3CA-mutant early breast cancer, supporting more personalized treatment strategies. #BreastCancer #GBG www.gbg.de
000
GBG @gbg.de · 08/05/2026
New insights from #ESMOBC: A modified Sinn regression grade combining tumor response and nodal status improved prognostic stratification after neoadjuvant therapy in breast cancer, supporting more personalized treatment decisions. #BreastCancer #GBG Visit our website: www.gbg.de
000
GBG @gbg.de · 04/02/2026
🧬 Today on #WorldCancerDay our thoughts are with everyone who is affected directly or indirectly by #cancer. At the same time, we want to highlight the enormous potential that #science now offers - especially for people with #breastcancer: #Molecular #Testing www.gbg.de/en/news/deta...
000
GBG @gbg.de · 08/01/2026
🔔 Reminder: Join us on March 12–13, 2026 for the 23rd Annual Scientific Meeting 2026 #ASM, a 2-day international #conference focusing on breast cancer. 👉 Registration is open now – make sure to secure the Early Bird rate by January 15: extern.gbg.events
000
GBG @gbg.de · 11/12/2025
🔍 #SABCS2025: #INSEMA Trial – #Radiotherapy Analysis (presented by Guido Hildebrandt) Today’s presentation offered important insights into how radiotherapy was actually applied among patients undergoing breast-conserving surgery with or without sentinel lymph node biopsy #SLNB in the INSEMA trial.
000
GBG @gbg.de · 11/12/2025
#SABCS2025 Update: #INSEMA – Secondary results presented by Toralf Reimer INSEMA Rando2 adds robust data on the oncological #safety of omitting cALND in patients with positive SLNB, under conditions of strict regional nodal irradiation #RNI and #radiotherapy quality assurance.
000
GBG @gbg.de · 11/12/2025
📣 Meet #GBG at #SABCS2025 – Highlights for December 11! A full and inspiring third day at the SABCS brought important new insights into #axillary #surgery, #radiotherapy strategies, #translational #biomarkers, and international collaborations shaping the future of #breast #cancer care.
020
GBG @gbg.de · 11/12/2025
At #SABCS2025, new translational results from the #NSABP B-59/GBG-96- #GeparDouze trial were presented by Carsten Denkert, highlighting how #TIL levels and molecular #TNBC subtypes shape response to #neoadjuvant immune-chemotherapy. ➡️ Full details are available here: www.gbg.de/news/detail/...
010
GBG @gbg.de · 10/12/2025
#SABCS2025: S. Loibl presented additional efficacy and safety data from the DESTINY-Breast05 trial, evaluating trastuzumab deruxtecan vs trastuzumab emtansine as post-NACT for pts with high-risk HER2-positive early breast cancer who did not achieve a pCR after standard NACT and anti-HER2 therapy.
000
GBG @gbg.de · 10/12/2025
📣 Meet #GBG at #SABCS2025 – Highlights for December 10! Another strong day for GBG at the San Antonio Breast Cancer Symposium with key data on #HER2+ early breast cancer, #TNBC immuno- #chemotherapy response #biology, and multiple high-impact external collaborations.
020
GBG @gbg.de · 10/12/2025
🧬 #SABCS2025 | Impact of Checkpoint Inhibition on Fertility in Young Women with Early TNBC Key Findings from the #NSABP B-59/GBG-96-GeparDouze Substudy presented by Mattea Reinisch ➡️ For more details and the full presentation, please visit the #GBG website: www.gbg.de/news/detail/... #GeparDouze
000
GBG @gbg.de · 10/12/2025
At #SABCS2025, Brooke M. Felsheim presented a pooled analysis of three major randomized trials - #BrighTNess, #CALGB40603, and #GeparSixto—providing one of the most comprehensive evaluations to date of #carboplatin in early-stage triple-negative breast cancer (TNBC).
000
GBG @gbg.de · 10/12/2025
📢 Key Findings from Our #SABCS2025 Presentation Prognostic Markers in Residual TNBC After Neoadjuvant Chemotherapy – Pooled Analysis from Nine #GBG/AGO-B Trials Presented by Johannes Holtschmidt ➡️ For more details and the full presentation, please visit the GBG website: www.gbg.de/news/detail/...
000
GBG @gbg.de · 09/12/2025
📣 Meet #GBG at #SABCS2025 – Highlights for December 9! 3 high-impact Rapid Fire Presentations featuring new analyses from leading #neoadjuvant and #immunotherapy trials. All presentation materials will be made available after the conference here: www.gbg.de/news/detail/...
000
GBG @gbg.de · 30/10/2025
PinkOctober – Research Brings Hope: #INSEMA Study #GBG75 📖 Most recent results have been published in #NEJM: www.nejm.org/doi/full/10.... Exciting news: the latest INSEMA data will be presented as an Oral Presentation at the San Antonio Breast Cancer Symposium #SABCS2025 this December.
010
GBG @gbg.de · 29/10/2025
#NeoRad study #GBG116: phase III trial investigating whether #preoperative radiotherapy can improve disease-free survival compared to #postoperative #radiotherapy after #neoadjuvant #chemotherapy in patients with high-risk early breast cancer. 👉 More information: www.gbg.de/en/trials/neorad
000
GBG @gbg.de · 29/10/2025
#PinkOctober - #ASCENT-05: Phase III study investigates whether #Sacituzumab #Govitecan in combination with #Pembrolizumab can further improve outcomes compared to physician’s choice of standard therapy in pts with early TNBC who still have residual invasive disease after NACT and surgery
000
GBG @gbg.de · 27/10/2025
Today at the #DGHO Annual Meeting 2025 #Cologne: #GBG presents exciting new research on combination therapy for #BRCA-mutated #breastcancer! Proud to share the #ELEMENT study #GBG114 — a randomized phase II trial exploring whether adding the oral #SERD #elacestrant to the #PARP inhibitor #olaparib.
000
GBG @gbg.de · 26/10/2025
Published in #BCR this year introduces a powerfulprediction model for pathological complete response in #HER2-negative #breastcancer, developed using data from more than 1,100 pts: observational Hannover Breast Cancer Study and randomized #GeparSepto #GBG69 and #GeparOcto #GBG84 #clinicaltrials.
000
GBG @gbg.de · 26/10/2025
In this #BreastCancerAwarenessMonth, we are excited to share that #GBG will have a strong scientific presence at the San Antonio Breast Cancer Symposium #SABCS2025 — one of the most important international meetings in breast cancer research. 💡
010
GBG @gbg.de · 23/10/2025
#BreastCancerAwarenessMonth2025: This October, as we raise awareness for #breastcancer and highlight the importance of long-term patient care, we invite all former study participants to take part in the #GBG071 #Registry 👉 Learn more and register here: www.gbg.de/en/trials/re...
000
GBG @gbg.de · 22/10/2025
#Flamingo-01 #GBG111: a global phase III, randomized, placebo-controlled study investigating the GLSI-100 immunotherapy in HLA-A*02-positive and HER2/neu-positive breast cancer patients who remain at high risk of #recurrence after completing both #neoadjuvant and #adjuvant standard therapy.
010
GBG @gbg.de · 22/10/2025
#PinkOctober: The study reveals that luminal breast tumors can dynamically change under #neoadjuvant #chemotherapy - with aggressive #Luminal B tumors often transitioning into a less aggressive Luminal A type. Read full publication here: www.cell.com/cancer-cell/...
000
GBG @gbg.de · 20/10/2025
#PinkOctober | #ESMO2025 #BMBC registry #GBG79 as poster presentation: The results highlight the importance of retesting #HER2 status in #metastatic sites and open the door to new, targeted treatment opportunities — even for patients previously classified as HER2-negative.
000
GBG @gbg.de · 20/10/2025
#ESMO2025 #GBG presented long-term results from #GeparNuevo trial #GBG96 providing new insights into the role of immunotherapy in early #TNBC - survival benefit for #PD-L1 inhibitor was showed. This is the only trial with benefit in combination with dose-dense chemotherapy without carboplatin!
000
GBG @gbg.de · 18/10/2025
#DESTINY-Breast05 trial #GBG103 at #ESMO2025: T-DXd as a potential new #SOC? The phase III study demonstrated statistically significant and clinically meaningful improvement in #IDFS #DFS with #T-DXd vs #T-DM1 in pts with high-risk #HER2-positive eBC who had residual invasive disease.
000
GBG @gbg.de · 18/10/2025
#GBG at #ESMO2025: As one of the leading research groups in breast cancer, we are proud to contribute to several presentations and discussions that will shape the future of oncology research. We’re looking forward to inspiring sessions, great scientific exchange at #ESMO25
000
GBG @gbg.de · 17/10/2025
#BreastCancerAwarenessWeek for Men with #BreastCancer 💙 As part of this awareness week, the #GBG would like to highlight a crucial topic for all individuals affected by breast cancer: molecular and genetic testing. Learn more: www.gbg.de/news/detail/... Workshop-Link: www.youtube.com/watch?v=_tIP...
000
GBG @gbg.de · 16/10/2025
#PinkOctober Spotlight: The #ETERNITY-B #Registry #GBG107 – a prospective and retrospective follow-up project dedicated to understanding the long-term #safety and #efficacy of #treatments used in #GBG #clinicaltrials for early-stage #breastcancer 👉 Learn more: www.gbg.de/en/trials/et...
000
GBG @gbg.de · 14/10/2025
#PinkOctober2025: #Leptomeningeal #metastases #LM remain one of the most severe complications in breast cancer, associated with a markedly poorer #prognosis than brain metastases without LM. This large #registry analysis highlights an urgent unmet clinical need: pmc.ncbi.nlm.nih.gov/articles/PMC...
000
GBG @gbg.de · 13/10/2025
#PinkOctober 2025 | Spotlight on BMBC Study – Understanding Brain #Metastases in Breast Cancer #BMBC 📰 What’s next: We’re excited to announce that new analyses from the BMBC registry will be presented at #ESMO25 and #SABCS25. Stay tuned for more details in the coming days! www.gbg.de/en/trials/bmbc
000
GBG @gbg.de · 12/10/2025
Hot from the Press | #BreastCancerScreening Works – New Data Show Significant Reduction in Mortality. Findings clearly demonstrate: Mammography screening saves lives – and remains a key pillar in reducing #breastcancer mortality in Germany: ZEBra-MSP project doris.bfs.de/jspui/handle...
000
GBG @gbg.de · 11/10/2025
#PinkOctober | Understanding #BreastCancer in #Pregnancy #BCP, #GBG29: With the trend toward later motherhood, the incidence of breast cancer during pregnancy is slowly increasing. Yet, data on how the disease and its treatment affect both mother and child remain limited. BCP aims to fill this gap.
000
GBG @gbg.de · 10/10/2025
#PinkOctober | #Publication on Breast Cancer Diagnosed During #Pregnancy in #npjBreastCancer: Findings provide important insights into the biology of pregnancy-associated breast cancer #PrBC and may guide future strategies for patient care. 👉 pmc.ncbi.nlm.nih.gov/articles/PMC...
010
GBG @gbg.de · 09/10/2025
#PinkOctober: #Cambria-2 Trial #GBG115: international phase III clinical trial exploring whether #SERD #Camizestrant can offer better protection against recurrence than standard adjuvant endocrine therapy in pts with early-stage ER+/HER2- breast cancer www.gbg.de/en/trials/ca...
000
GBG @gbg.de · 08/10/2025
#PinkOctober: we highlight the #Cambria-1 #GBG110 trial – a study that offers new perspectives for pts with early-stage ER+/HER2- #breastcancer Goal: Compare invasive breast cancer-free survival between pts receiving #Camizestrant and those continuing on standard therapy 👉 www.gbg.de/en/trials/ca...
000
GBG @gbg.de · 07/10/2025
In The Lancet Regional Health – Europe: important real-world insights into the prevalence and prognosis of pts with early ER+/HER2- breast cancer who may be eligible for adjuvant CDK4/6 inhibitors: #monarchE and #NATALEE compared to #PANTHER trial #GBG53 www.sciencedirect.com/science/arti...
000
GBG @gbg.de · 07/10/2025
Pink October: #GBG highlight a special offer: interactive #workshops “Brustkrebs kompakt erklärt” These online workshops are designed to provide scientifically sound, practice-oriented knowledge at the highest level, aligned with the latest state of #BreastCancer research: www.workshops.gbg.events
000
GBG @gbg.de · 05/10/2025
Spotlight on the #MOMENTUM study #GBG 108 – a prospective, non-interventional, translational registry study. 🧬 By analyzing #tumor tissue and #ctDNA, we seek to uncover how tumors evolve over time – and how therapies can be made more precise and effective. 👉 www.gbg.de/studien/mome...
010
GBG @gbg.de · 04/10/2025
Progress in breast cancer (BC) research: #TAXIS - phase III trial exploring innovative treatment strategies for pts with clinically node-positive BC. The study evaluates tailored axillary surgery +/- lymph node dissection, followed by radiotherapy. Publication: www.ejcancer.com/article/S095... #GBG
000
GBG @gbg.de · 03/10/2025
Driving Innovation in Breast Cancer Research! At #GBG, we cover the full spectrum of breast cancer #treatment – always striving to improve outcomes for patients. Our strength lies in investigator-initiated, academically driven trials, complemented by service studies for our partners. www.gbg.de
000
GBG @gbg.de · 02/10/2025
📰 Final survival results of #PENELOPE-B trial: While routine adjuvant palbociclib cannot be recommended for all HR+/HER2− early breast cancers (BC), the results point to importance of histological subtypes. For lobular BC CDK4/6 inhibition hold new promise: www.annalsofoncology.org/article/S092...
000
GBG @gbg.de · 01/10/2025
Today marks the start of Pink October – the international Breast Cancer Awareness Month: To provide guidance and clarity, we are sharing an insight into the #GBG patient journey slider from our homepage: www.gbg.de/en/patients #BreastCancerAwarenessMonth #PinkOctober #BreastCancer #ClinicalTrials
000